Roger B. Cohen, MD; Jorge M. Abdallah, MD; James R. Gray, LCDR, MS, USNR; Francine Foss, MD
Fludarabine phosphate is approved for the treatment of advanced B-cell chronic lymphocytic leukemia refractory to alkylating agents. We report two cases of disabling but reversible neurotoxicity in a patient with mycosis fungoides and a patient with chronic lymphocytic leukemia who received standard doses of fludarabine (20 to 25 mg/m2 per day for 5 days) every 28 days for 6 to 8 cycles. Serial brain magnetic resonance imaging scans in the patient with mycosis fungoides showed rapid evolution of white-matter changes with subsequent complete resolution.
Cohen RB, Abdallah JM, Gray JR, Foss F. Reversible Neurologic Toxicity in Patients Treated with Standard-Dose Fludarabine Phosphate for Mycosis Fungoides and Chronic Lymphocytic Leukemia. Ann Intern Med. ;118:114–116. doi: 10.7326/0003-4819-118-2-199301150-00007
Download citation file:
Published: Ann Intern Med. 1993;118(2):114-116.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use